Physician profile
Julia D Borkowicz
NPI 1720216823
$10,581.98
in general payments reported to CMS, 2019-2025
34 companies · $2,384 in 2025
The $2,384 reported for 2025 was more than what 93% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,604 · 2022: $1,912 · 2023: $2,350 · 2024: $2,332 · 2025: $2,384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,049 · Education: $16.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,049.17 |
| Education | $16.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,255.27 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,579.04 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $1,086.93 | 2022-2025 | Tremfya, Stelara, Simponi |
| Genzyme Corporation | $416.97 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $404.55 | 2024-2025 | Zenpep, Vowst |
| Takeda Pharmaceuticals U.S.A., INC. | $346.54 | 2021-2024 | Eohilia, Entyvio |
| Celgene Corporation | $336.34 | 2022-2024 | Zeposia |
| Pfizer INC. | $332.66 | 2021-2025 | |
| Lilly USA, LLC | $287.47 | 2023-2025 | Omvoh |
| Ardelyx, INC. | $284.84 | 2022-2025 | Ibsrela |
| Redhill Biopharma INC. | $278.66 | 2021-2023 | Talicia, Movantik, Aemcolo |
| Qol Medical, LLC | $276.73 | 2021-2025 | Sucraid |
| Phathom Pharmaceuticals, INC. | $252.21 | 2024-2025 | Voquezna |
| Celltrion USA INC. | $157.27 | 2024-2025 | Vegzelma, Zymfentra |
| Daiichi Sankyo INC. | $139.96 | 2021-2022 |
Show all 34 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Borkowicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.